Page 177 of 440: studies 1,761 to 1,770 of 4,392, newest first. Back to the psilocybin overview
November 7, 2012 Nicolas Langlitz
Abstract Chapter 2, “Swiss Psilocybin and US Dollars,” turns to the situation in Switzerland where proto-countercultural experiments in living have blossomed since the beginning of the twentieth century without ever leading to the kind of aggressive confrontations that the United States experienced in the 1960s. The government official overseeing the comeback of hallucinogen research in this...
Journal of Psychoactive Drugs November 1, 2012 Michael Lyvers, Molly Meester 97 citations
Psychedelic drugs have long been known to be capable of inducing mystical or transcendental experiences. However, given the common "recreational" nature of much present-day psychedelic use, with typical doses tending to be lower than those commonly taken in the 1960s, the extent to which illicit use of psychedelics today is associated with mystical experiences is not known. Furthermore the mild...
Schizophrenia Bulletin October 6, 2012 Robin Carhart-Harris, Robert Leech, David Erritzøe et al. 267 citations
Psilocybin is a classic psychedelic and a candidate drug model of psychosis. This study measured the effects of psilocybin on resting-state network and thalamocortical functional connectivity (FC) using functional magnetic resonance imaging (fMRI). Fifteen healthy volunteers received intravenous infusions of psilocybin and placebo in 2 task-free resting-state scans. Primary analyses focused on...
Drug Testing and Analysis August 9, 2012 Manuela Pellegrini, Maria Concetta Rotolo, Emilia Marchei et al. 21 citations
“Magic mushrooms” is the most common name given to hallucinogenic fungi containing the psychoactive alkaloids psilocybin and psilocin. In recent years, fungis' sclerotia, commonly called “magic truffles” have become a form of supply of psychoactive Psilocybe alkaloids since Psilocybe sclerotia are not specifically included in the laws banning the sale, the purchase and the use of such...
Psychopharmacology July 26, 2012 André Schmidt, Michael Kometer, Rosilla Bachmann et al. 94 citations
RationaleBoth glutamate and serotonin (5-HT) play a key role in the pathophysiology of emotional biases. Recent studies indicate that the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine and the 5-HT receptor agonist psilocybin are implicated in emotion processing. However, as yet, no study has systematically compared their contribution to emotional biases.ObjectivesThis study...
July 9, 2012 Amitava Dasgupta
This chapter contains sections titled: Introduction Magic Mushroom Abuse Peyote Cactus: Use and Abuse Abuse of Khat and Related Compounds Solvent and Glue Abuse Conclusions References
Drug and Alcohol Dependence June 1, 2012 Matthew W Johnson, R Andrew Sewell, Roland R. Griffiths 121 citations
Psilocybin is a well-characterized classic hallucinogen (psychedelic) with a long history of religious use by indigenous cultures, and nonmedical use in modern societies. Although psilocybin is structurally related to migraine medications, and case studies suggest that psilocybin may be efficacious in treatment of cluster headache, little is known about the relationship between psilocybin and...
Biological Psychiatry May 9, 2012 Michael Kometer, André Schmidt, Rosilla Bachmann et al. 300 citations
BackgroundSerotonin (5-HT) 1A and 2A receptors have been associated with dysfunctional emotional processing biases in mood disorders. These receptors further predominantly mediate the subjective and behavioral effects of psilocybin and might be important for its recently suggested antidepressive effects. However, the effect of psilocybin on emotional processing biases and the specific...
The FASEB Journal April 1, 2012 Evan J. Kyzar, Christopher Collins, Jeremy Green et al. 1 citation
Mescaline, phencyclidine (PCP) and psilocybin are potent hallucinogenic drugs strongly affecting both human and animal behavior. However, these compounds have not been previously investigated in zebrafish (Danio rerio), rapidly gaining popularity as a model in psychopharmacology research. Here, we examine the effects of mescaline, PCP and psilocybin in multiple behavioral paradigms. Mescaline...
PLoS One February 17, 2012 Erich Studerus, Alex Gamma, Michael Kometer et al. 372 citations
Responses to hallucinogenic drugs, such as psilocybin, are believed to be critically dependent on the user's personality, current mood state, drug pre-experiences, expectancies, and social and environmental variables. However, little is known about the order of importance of these variables and their effect sizes in comparison to drug dose. Hence, this study investigated the effects of 24...